» Articles » PMID: 39851576

Detection of Cancer Stem Cells from Patient Samples

Overview
Journal Cells
Publisher MDPI
Date 2025 Jan 24
PMID 39851576
Authors
Affiliations
Soon will be listed here.
Abstract

The existence of cancer stem cells (CSCs) in various tumors has become increasingly clear in addition to their prominent role in therapy resistance, metastasis, and recurrence. For early diagnosis, disease progression monitoring, and targeting, there is a high demand for clinical-grade methods for quantitative measurement of CSCs from patient samples. Despite years of active research, standard measurement of CSCs has not yet reached clinical settings, especially in the case of solid tumors. This is because detecting this plastic heterogeneous population of cells is not straightforward. This review summarizes various techniques, highlighting their benefits and limitations in detecting CSCs from patient samples. In addition, methods designed to detect CSCs based on secreted and niche-associated signaling factors are reviewed. Spatial and single-cell methods for analyzing patient tumor tissues and noninvasive techniques such as liquid biopsy and in vivo imaging are discussed. Additionally, methods recently established in laboratories, preclinical studies, and clinical assays are covered. Finally, we discuss the characteristics of an ideal method as we look toward the future.

References
1.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

2.
Zhang Q, Ding J, Liu J, Wang W, Zhang F, Wang J . -infected MSCs acquire a pro-inflammatory phenotype and induce human gastric cancer migration by promoting EMT in gastric cancer cells. Oncol Lett. 2016; 11(1):449-457. PMC: 4726974. DOI: 10.3892/ol.2015.3897. View

3.
de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

4.
Lowes L, Hedley B, Keeney M, Allan A . User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch® system. Cytometry A. 2012; 81(11):983-95. DOI: 10.1002/cyto.a.22158. View

5.
Wood B, Jevremovic D, Bene M, Yan M, Jacobs P, Litwin V . Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria. Cytometry B Clin Cytom. 2013; 84(5):315-23. DOI: 10.1002/cyto.b.21108. View